<DOC>
	<DOCNO>NCT02564146</DOCNO>
	<brief_summary>ALPACA interventional , multicentre , open-label , randomized active-controlled phase II trial two arm . To estimate treatment effect overall survival , feasibility , efficacy safety alternate treatment cycle gemcitabine monotherapy follow nab-paclitaxel/gemcitabine relative standard continue nab-paclitaxel/gemcitabine cycle first-line treatment metastatic pancreatic cancer patient receive 3 cycle induction therapy standard nab-paclitaxel/gemcitabine .</brief_summary>
	<brief_title>First-line Treatment Metastatic Pancreatic Cancer With Nab-paclitaxel Gemcitabine</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Adult patient ( ≥ 18 year age ) Histologically cytologically confirm metastatic adenocarcinoma pancreas . Patients islet cell neoplasms exclude . Karnofsky Perfomance Status ( KPS ) ≥ 70 % At least one unidimensionally measurable lesion assess CT scan Magnetic resonance imaging ( MRI ) accord Response Evaluation Criteria In Solid Tumors ( RECIST1.1 ) , Total bilirubin ≤ 1.5 x ULN ( Upper Limit Normal ) . Patients biliary stent may include provided bilirubin level stent insertion decrease ≤ 1.5 x ULN cholangitis . Adequate renal , hepatic bone marrow function , define Calculated creatinine clearance ≥ 30 mL/min accord CKDEPI formula ( Chronic kidney Disease Epidemiology Collaboration ) AST/GOT and/or ALT/GPT ≤ 2.5 x ULN ≤ 5.0 x ULN case liver metastasis Absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9/L Haemoglobin ≥ 9 g/dL Platelets ≥ 100 x 100 x 10^9/L Females Childbearing Potential ( FCBP ) must negative serum pregnancy test within 7 day first application study treatment must agree undergo pregnancy test randomization end treatment visit FCBP must either agree use able take effective contraceptive birth control measure ( Pearl Index &lt; 1 ) agree practice complete abstinence heterosexual intercourse course study least 1 month last application study treatment . A female subject consider childbearing potential unless age ≥ 50 year naturally amenorrhoeic ≥ 2 year , unless surgically sterile . Males must agree father child course trial least 6 month last administration study drug . Signed date informed consent start specific protocol procedures Patient 's legal capacity consent study participation Missing histological cytological confirmation metastatic adenocarcinoma pancreas Locally advance pancreatic adenocarcinoma without metastasis Any previous radiotherapy , surgery , chemotherapy investigational therapy treatment metastatic disease . ( Prior adjuvant chemotherapy gemcitabine fluoropyrimidine curative intent allow terminate 6 month first application study treatment . Previous palliative radiotherapy bonemetastases alleviation pain permit provide irradiated bone metastasis target lesion . ) Known brain metastase/brain metastasis . Brain imaging require symptomatic patient rule brain metastasis , require asymptomatic patient . Preexisting peripheral neuropathy ≥ grade 2 accord CTCAE version 4 ( Common Terminology Criteria Adverse Events ) • Medical history interstitial lung disease ( ILD ) pulmonary fibrosis Patients high cardiovascular risk , include , limited , recent coronary stenting myocardial infarction past year . Uncontrolled severe illness medical condition ( include uncontrolled diabetes mellitus ) Any severe concomitant disease disorder , could influence patient 's ability participate study his/her safety study interfere interpretation study result e.g . severe hepatic , renal , pulmonary , metabolic , psychiatric disorder Previous concurrent tumor underlie tumor disease ( pancreatic cancer ) exception cervical cancer situ , adequately treat basal cell carcinoma squamous cell carcinoma skin , superficial bladder tumor ( Ta , Tis , T1 ) curatively treat tumor &gt; 5 year prior enrolment Hypersensitivity nabpaclitaxel , gemcitabine , excipients drug Continuing abuse alcohol , drug , medical drug Pregnant female , breast feeding female females childbearing potential unable perform adequate contraceptive measure practice complete abstinence heterosexual intercourse Participation clinical trial treatment experimental drug within 28 day enrolment study study participation end treatment visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>